Study identifier:D5133N00007
ClinicalTrials.gov identifier:NCT03212287
EudraCT identifier:N/A
CTIS identifier:N/A
Brilinta tablets 60mg/90mg Clinical Experience Investigation
acute coronary syndrome, old myocardial infarction
N/A
No
-
All
663
Observational
16 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2024 by AstraZeneca
AstraZeneca
-
To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as “BRILINTA”) in clinical practice in the post-marketing phase. (1) Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on bleeding, dyspnoea and bradyarrhythmia so as to investigate onset, outcome, treatment for the event, and risk factors for these events, etc. (2) Profile and incidence of ADRs not expected from “Precautions for Use” of the ticagrelor JPI (3) Efficacy: Profile and incidence of cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke) (4) Factors which may affect safety or efficacy of ticagrelor
Location
Location
Hokkaido, Japan, 078-8211
Location
Hokkaido, Japan, 004-0052
Location
Hokkaido, Japan, 063-0005
Location
Hokkaido, Japan, 093-0076
Location
Miyagi, Japan, 980-0873
Location
Akita, Japan, 015-0834
Location
Yamagata, Japan, 992-0601
Location
Ibaraki, Japan, 300-0812
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.